A comparative study of insulin and glyburide versus glyburide or insulin in the chronic control of patients with type-2 diabetes

In order to know the usefulness of a combined treatment with gliburide and NPH insulin 25 patients with well controlled type II diabetes mellitus were studied. The patients were randomly divided in to three groups: Group I just received gliburide, Group II only insulin and Group III gliburide and in...

Full description

Saved in:

Bibliographic Details
Published in:	Gaceta médica de México Vol. 129; no. 6; p. 383
Main Authors:	Cortes Aguirre, H, Espinosa López, F R, Angulo Cervera, J A, Díaz Torres, J
Format:	Journal Article
Language:	Spanish
Published:	Mexico 01-11-1993
Subjects:	Adult Analysis of Variance Blood Glucose - analysis Blood Glucose - drug effects Chronic Disease Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Drug Therapy, Combination Female Glyburide - therapeutic use Glycated Hemoglobin A - analysis Glycated Hemoglobin A - drug effects Humans Insulin - therapeutic use Male Middle Aged
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In order to know the usefulness of a combined treatment with gliburide and NPH insulin 25 patients with well controlled type II diabetes mellitus were studied. The patients were randomly divided in to three groups: Group I just received gliburide, Group II only insulin and Group III gliburide and insulin. Glucose in fast, glycosylated haemoglobin and C peptide levels were determined over five months. For the statistical data processing variance analysis was performed. The initial and final glucose determinations were: Group I, 169.3 mg% and 139.0 mg% respectively (p > 0.05); Group II, 202.1 mg% and 177 mg% (p > 0.05); Group III, 157.8 mg% and 158.8 mg% (p > 0.1) for the glycosylated haemoglobin the determinations were: Group I, 7.2% and 5.1% (p > 0.05); Group II, 6.2% and 5.1% (p > 0.05) and Group III, 5.7% and 4.7% (p > 0.05). For the C peptide were 2.5 and 4.5 for Group I (p > 0.05), 2 and 4.1 for Group II (p > 0.05) and 3.2 and 5.3 for Group III (p > 0.05) with no significant statistical differences. It is concluded that the combined treatment showed to be effective, but not superior, in order to control diabetic patients and it can be a useful therapeutic alternative in well selected patients.
ISSN:	0016-3813